Cargando…
Severe acute respiratory syndrome coronavirus 2 infection in those on mepolizumab therapy
Autores principales: | Azim, Adnan, Pini, Laura, Khakwani, Zeeshan, Kumar, Santosh, Howarth, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7804376/ https://www.ncbi.nlm.nih.gov/pubmed/33453381 http://dx.doi.org/10.1016/j.anai.2021.01.006 |
Ejemplares similares
-
Prospective Italian real‐world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports
por: Pini, Laura, et al.
Publicado: (2021) -
M403 COVID-19 IN A PATIENT WITH HYPER-EOSINOPHILIC SYNDROME TREATED WITH MEPOLIZUMAB
por: Khakwani, Z., et al.
Publicado: (2020) -
Eosinophil‐derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma
por: Howarth, Peter, et al.
Publicado: (2020) -
Fungal sensitization and its relationship to mepolizumab response in patients with severe eosinophilic asthma
por: Wardlaw, Andrew, et al.
Publicado: (2020) -
Response to case report: Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy
por: Pouliquen, I. J., et al.
Publicado: (2017)